SEC Form 4 · accession 0001209191-17-063683
Sarepta Therapeutics, Inc. · SRPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hans Lennart Rudolf Wigzell
Director
Period of report
Nov 30, 2017
Accepted (ET)
Dec 4, 2017 · 8:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000873303
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 30, 2017 | M | 6,667 | $7.38 | A | 13,333 | D | |
| Common StockF1 | Nov 30, 2017 | S | 6,667 | $55.89 | D | 6,666 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Options (right to buy)F1 | $7.38 | Nov 30, 2017 | M | 6,667 | D | Jul 23, 2009 | Jul 23, 2018 | Common Stock | 6,667 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.87 to $55.93, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above.